CN101182585B - 一种鉴别hbv基因突变类型的方法及其专用芯片与试剂盒 - Google Patents
一种鉴别hbv基因突变类型的方法及其专用芯片与试剂盒 Download PDFInfo
- Publication number
- CN101182585B CN101182585B CN2007101793299A CN200710179329A CN101182585B CN 101182585 B CN101182585 B CN 101182585B CN 2007101793299 A CN2007101793299 A CN 2007101793299A CN 200710179329 A CN200710179329 A CN 200710179329A CN 101182585 B CN101182585 B CN 101182585B
- Authority
- CN
- China
- Prior art keywords
- sequence
- primer
- bar code
- deoxyribonucleotide
- kinds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 42
- 206010064571 Gene mutation Diseases 0.000 title claims abstract description 20
- 239000003153 chemical reaction reagent Substances 0.000 title abstract description 6
- 239000000523 sample Substances 0.000 claims abstract description 98
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 61
- 241000700721 Hepatitis B virus Species 0.000 claims abstract description 16
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims abstract description 8
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims abstract description 7
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 60
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 60
- 239000002773 nucleotide Substances 0.000 claims description 40
- 125000003729 nucleotide group Chemical group 0.000 claims description 40
- 238000009396 hybridization Methods 0.000 claims description 39
- 230000000869 mutational effect Effects 0.000 claims description 35
- 238000001514 detection method Methods 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 23
- 230000003321 amplification Effects 0.000 claims description 21
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 21
- 238000012360 testing method Methods 0.000 claims description 16
- 208000002672 hepatitis B Diseases 0.000 claims description 14
- 238000007403 mPCR Methods 0.000 claims description 13
- 150000007523 nucleic acids Chemical group 0.000 claims description 12
- 230000008878 coupling Effects 0.000 claims description 10
- 238000010168 coupling process Methods 0.000 claims description 10
- 238000005859 coupling reaction Methods 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 238000003149 assay kit Methods 0.000 claims 5
- 230000035772 mutation Effects 0.000 abstract description 11
- 108060002716 Exonuclease Proteins 0.000 abstract description 2
- 102000013165 exonuclease Human genes 0.000 abstract description 2
- 108700024845 Hepatitis B virus P Proteins 0.000 description 45
- 230000008859 change Effects 0.000 description 36
- 239000013612 plasmid Substances 0.000 description 33
- 108020004414 DNA Proteins 0.000 description 23
- 238000004519 manufacturing process Methods 0.000 description 17
- 239000000203 mixture Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000003908 quality control method Methods 0.000 description 12
- 238000012408 PCR amplification Methods 0.000 description 11
- 238000011144 upstream manufacturing Methods 0.000 description 10
- 125000003368 amide group Chemical group 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 239000002751 oligonucleotide probe Substances 0.000 description 7
- 239000006210 lotion Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 238000006384 oligomerization reaction Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- -1 methane amide Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101150084044 P gene Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 230000000192 social effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101793299A CN101182585B (zh) | 2007-12-12 | 2007-12-12 | 一种鉴别hbv基因突变类型的方法及其专用芯片与试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101793299A CN101182585B (zh) | 2007-12-12 | 2007-12-12 | 一种鉴别hbv基因突变类型的方法及其专用芯片与试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101182585A CN101182585A (zh) | 2008-05-21 |
CN101182585B true CN101182585B (zh) | 2010-06-09 |
Family
ID=39448010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101793299A Active CN101182585B (zh) | 2007-12-12 | 2007-12-12 | 一种鉴别hbv基因突变类型的方法及其专用芯片与试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101182585B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102676654B (zh) * | 2011-03-17 | 2014-09-24 | 中国科学院微生物研究所 | 一种检测基因突变的方法 |
CN102230025B (zh) * | 2011-06-08 | 2014-04-23 | 中国人民解放军第四军医大学 | 一种用于乙型肝炎病毒基因耐药突变检测的试剂盒及检测方法 |
CN102994519B (zh) * | 2011-09-15 | 2016-06-15 | 蔡志明 | 化学合成的HBV 1.2x基因组、表达系统及其构建方法 |
CN103088151B (zh) * | 2012-08-15 | 2014-07-23 | 浙江大学 | 用于乙型肝炎病毒四色荧光定量pcr检测的试剂盒及应用 |
CN104846074B (zh) * | 2015-03-26 | 2017-12-22 | 珠海赛乐奇生物技术股份有限公司 | 用于torch检测的探针、基因芯片和试剂盒 |
CN107022607B (zh) * | 2017-03-16 | 2019-01-22 | 北京博奥晶典生物技术有限公司 | 通过碱基错配解决多重pcr时等位基因扩增不平衡的方法 |
CN107937507B (zh) * | 2017-11-17 | 2021-06-01 | 中国人民解放军第三〇二医院 | 一种可溶性微针贴片及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1834261A (zh) * | 2005-11-15 | 2006-09-20 | 北京博奥生物芯片有限责任公司 | 基因分型芯片及其制备方法与应用 |
CN1840695A (zh) * | 2006-02-08 | 2006-10-04 | 北京博奥生物芯片有限责任公司 | 一种序列特异性寡核苷酸探针及其应用 |
CN1896284A (zh) * | 2006-06-30 | 2007-01-17 | 博奥生物有限公司 | 一种鉴别等位基因类型的方法 |
WO2007084567A2 (en) * | 2006-01-17 | 2007-07-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Detection and discrimination of hepatitis c virus, human immunodeficiency virus type-1 and hepatitis b virus |
-
2007
- 2007-12-12 CN CN2007101793299A patent/CN101182585B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1834261A (zh) * | 2005-11-15 | 2006-09-20 | 北京博奥生物芯片有限责任公司 | 基因分型芯片及其制备方法与应用 |
WO2007084567A2 (en) * | 2006-01-17 | 2007-07-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Detection and discrimination of hepatitis c virus, human immunodeficiency virus type-1 and hepatitis b virus |
CN1840695A (zh) * | 2006-02-08 | 2006-10-04 | 北京博奥生物芯片有限责任公司 | 一种序列特异性寡核苷酸探针及其应用 |
CN1896284A (zh) * | 2006-06-30 | 2007-01-17 | 博奥生物有限公司 | 一种鉴别等位基因类型的方法 |
Non-Patent Citations (6)
Title |
---|
Jang H et al..Oligonucleotide chip for detection of Lamivudine-resistanthepatitis Bvirus.J Clin Microbiol42 9.2004,42(9),4181-4188. |
Jang H et al..Oligonucleotide chip for detection of Lamivudine-resistanthepatitis Bvirus.J Clin Microbiol42 9.2004,42(9),4181-4188. * |
赵伟等.基因芯片检测拉米夫定治疗慢性乙型肝炎过程中HBV变异技术的建立和应用.中华实验和临床病毒学杂志17 4.2003,17(4),339-343. |
赵伟等.基因芯片检测拉米夫定治疗慢性乙型肝炎过程中HBV变异技术的建立和应用.中华实验和临床病毒学杂志17 4.2003,17(4),339-343. * |
陈士俊 等.DNA芯片分析HBV阅读框架多点基因突变的研究.中华实验和临床病毒学杂志18 4.2004,18(4),373-376. |
陈士俊 等.DNA芯片分析HBV阅读框架多点基因突变的研究.中华实验和临床病毒学杂志18 4.2004,18(4),373-376. * |
Also Published As
Publication number | Publication date |
---|---|
CN101182585A (zh) | 2008-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11041189B2 (en) | Genetic markers for discrimination and detection of a virus causing red sea bream iridovirus disease which is an infectious aquatic organism disease, and method of discriminating and detecting the virus using the same | |
CN1896284B (zh) | 一种鉴别等位基因类型的方法 | |
CN101182585B (zh) | 一种鉴别hbv基因突变类型的方法及其专用芯片与试剂盒 | |
US20110269192A1 (en) | Loop-shaped primer used in nucleic acid amplification and the use thereof | |
CN107034277A (zh) | 一种检测低丰度基因突变的方法 | |
US10519484B2 (en) | Lytic composition and application thereof, kit, method for preparing nucleic acid by utilizing lytic composition, and nucleic acid analysis method | |
KR101644773B1 (ko) | 어류 에드와드 감염증과 연쇄구균 감염증 원인세균의 판별 및 검출용 유전자 마커, 및 이를 이용한 원인세균의 판별 및 검출 방법 | |
CA2365870A1 (en) | Typing of human enteroviruses | |
US20110306505A1 (en) | X-STR multiplex PCR amplification system | |
CN104611422A (zh) | 一种检测大肠杆菌耐氟喹诺酮类gyrA、parC基因点突变方法 | |
CN110791577A (zh) | 一种检测结核分枝杆菌异烟肼耐药突变基因的试剂盒及方法 | |
KR20150136558A (ko) | Pna 프로브 및 형광융해곡선분석을 이용한 혈액형 판별방법 | |
CN108374042A (zh) | 离子激流基因组测序 | |
CN108060213B (zh) | 基于探针导向的重组酶介导的等温扩增法检测snp位点用探针和试剂盒 | |
CN105177118B (zh) | 检测人egfr基因突变的引物和探针体系及试剂盒 | |
KR101287431B1 (ko) | 표적 유전자의 다양한 변이가 존재하는 유전자 영역을 증폭하기 위한 프라이머 조성물, 이를 이용한 표적 유전자 증폭 방법 및 이를 포함하는 pcr 증폭 키트 그리고 이를 이용한 표적 유전자의 유전자형 분석방법 | |
KR102683325B1 (ko) | 헬리코박터 파일로리(Helicobacter pylori) 유전형 판별용 PNA 프로브 및 이를 이용한 헬리코박터 파일로리 유전형 판별방법 | |
CN103014135A (zh) | 一种鉴定结核分枝杆菌的方法 | |
KR101727598B1 (ko) | Pna 프로브 및 융해곡선분석을 이용한 미토콘드리아 dna의 snp 분석방법 | |
KR101655069B1 (ko) | 잉어 허피스 바이러스 그레이 에스피에이치 판별용 유전자 마커, 및 이를 이용한 원인바이러스의 판별 방법 | |
KR101655068B1 (ko) | 잉어 허피스 바이러스 베르코이버 티케이 판별용 유전자 마커, 및 이를 이용한 원인바이러스의 판별 방법 | |
KR101655071B1 (ko) | 참돔 이리도 바이러스 판별용 유전자 마커, 및 이를 이용한 원인바이러스의 판별 방법 | |
KR20140128555A (ko) | 마이크로시스티스속 균주의 유전자 증폭용 프라이머 및 이를 이용한 마이크로시스티스속 균주의 탐지방법 | |
CN107287309A (zh) | 一种血液循环肿瘤dna点突变检测方法 | |
KR101737322B1 (ko) | 잉어봄바이러스병 바이러스 검출용 유전자 마커, 및 이를 이용한 바이러스의 검출 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: CAPITALBIO CORPORATION CO., LTD. Free format text: FORMER NAME: CAPITALBIO CORPORATION |
|
CP01 | Change in the name or title of a patent holder |
Address after: 102206 Beijing City, Changping District Life Science Park Road No. 18 Patentee after: CAPITALBIO CORPORATION Patentee after: Tsinghua University Address before: 102206 Beijing City, Changping District Life Science Park Road No. 18 Patentee before: Capitalbio Corporation Patentee before: Tsinghua University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180320 Address after: 101111 Beijing branch of Beijing economic and Technological Development Zone Street 88 Hospital No. 10 Building Room 101 Co-patentee after: Tsinghua University Patentee after: CAPITALBIO TECHNOLOGY CO., LTD. Address before: 102206 Beijing City, Changping District Life Science Park Road No. 18 Co-patentee before: Tsinghua University Patentee before: CAPITALBIO CORPORATION |